Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

425 results about "PEGylation" patented technology

PEGylation (often styled pegylation) is the process of both covalent and non-covalent attachment or amalgamation of polyethylene glycol (PEG, in pharmacy called macrogol) polymer chains to molecules and macrostructures, such as a drug, therapeutic protein or vesicle, which is then described as PEGylated (pegylated). PEGylation is routinely achieved by the incubation of a reactive derivative of PEG with the target molecule. The covalent attachment of PEG to a drug or therapeutic protein can "mask" the agent from the host's immune system (reducing immunogenicity and antigenicity), and increase its hydrodynamic size (size in solution), which prolongs its circulatory time by reducing renal clearance. PEGylation can also provide water solubility to hydrophobic drugs and proteins. Having proven its pharmacological advantages and acceptability, PEGylation technology is the foundation of a growing multibillion-dollar industry.

Antioxidant peptide based on mussel byssus, preparation method, preparation and application thereof

ActiveCN120081905ACosmetic preparationsMake-upDisulfide bondingDisulphide bond formation
The invention relates to the technical field of bioactive peptides, in particular to an antioxidant peptide based on mussel byssus, a preparation method, a preparation and application of the antioxidant peptide based on mussel byssus, the antioxidant peptide is designed and synthesized by referring to the structural characteristics of mussel byssus proteins mfp-3, mfp-5 and mfp-6, the antioxidant peptide comprises four sequences of MFP3-AP1, MFP5-AP2, MFP6-AP3 and MFP-Hybrid, tyrosine in the peptide is modified into DOPA through enzymatic modification, and the antioxidant peptide is prepared through enzymatic modification. The stability and activity of the antioxidant peptide are enhanced through disulfide bond formation, metal ion coordination, PEGylation and other modifications, and the antioxidant peptide has high DPPH free radical scavenging activity, ABTS free radical scavenging activity, hydroxyl free radical scavenging activity and iron ion reducing capacity, has a protective effect on the cellular level, can be prepared into a liquid preparation, a freeze-dried preparation or a micro-capsule preparation, and can be used for preparing the antioxidant peptide. The compound is expected to be applied to the fields of antioxidant health care products, cosmetics and medicines.
Owner:CHENGDU UNIV

Biomineralization material for treating dentin hypersensitivity and promoting epitaxial growth of enamel, and use thereof

The provided is a biomineralization material for treating dentin hypersensitivity and promoting epitaxial growth of enamel and a use thereof. The biomineralization material includes following raw materials in parts by weight: 5-72 parts of a film-forming protein or a PEGylated film-forming protein, 4-67 parts of a water-soluble disulfide bond exchanger and 1-21 parts of a pH regulator. The present application proposes for the first time that the disulfide bond exchanger (e.g., cysteine (Cys)) without any toxicity may react with the film-forming protein or PEGylated film-forming protein. When a protein nano-coating with a mineralization regulating function is formed, no large number of macromolecular protein aggregates can be generated to block the dentin pores. The biomineralization material can permeate deeply into the exposed dentin pores, with the depth of 200-500 μm (the sealing depth of the protein coating reacting with TCEP is only about 40 μm).
Owner:SHAANXI NORMAL UNIV

Bionic vesicle preparation as well as preparation method and application thereof

The invention belongs to the technical field of bionic nano-drugs, and particularly relates to a bionic vesicle preparation as well as a preparation method and application thereof. The bionic vesicle preparation disclosed by the invention is prepared from the following raw materials: mesenchymal stem cell outer vesicles, nintedanib and DSPE-PEG-HA (hyaluronic acid modified pegylated phospholipid); the nintedanib is loaded in the mesenchymal stem cell outer vesicle, and the DSPE-PEG-HA is coupled to the surface of the mesenchymal stem cell outer vesicle. The bionic vesicle preparation disclosed by the invention can be used for directly delivering a drug to a pulmonary fibrosis injury part through inhalation type drug delivery, and acting on a focus part at a higher local concentration, meanwhile, the exposure of the drug in whole-body circulation is remarkably reduced, the occurrence of side effects is reduced, and the specific targeting intervention and regulation on fibroblasts are realized.
Owner:LUOYANG CENT HOSPITAL

Synthetic peptide compounds and methods of use

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.
Owner:REALTA HLDG LLC +2

Pegylated cellulose nanocrystal as well as preparation method and application thereof

The invention relates to a pegylated cellulose nanocrystal and a preparation method and application thereof, in particular to the technical field of nanomaterials, the preparation method comprises the following steps: modifying polyethylene glycol into chlorinated polyethylene glycol; carrying out alkaline treatment on the cellulose nanocrystal to enhance the activity of the cellulose nanocrystal; then mixing and reacting the polyethylene glycol cellulose nanocrystal and the polyethylene glycol cellulose nanocrystal to obtain a polyethylene glycol cellulose nanocrystal; according to the invention, polyethylene glycol is grafted on the surface of the cellulose nanocrystal through chemical reaction, so that the action mechanism of the cellulose nanocrystal is changed and enhanced, on one hand, the grafting of polyethylene glycol not only exerts the steric hindrance effect, but also enhances the characteristics (crystallinity, thermal stability and dispersity) of the cellulose nanocrystal; on the other hand, due to the existence of polyethylene glycol, the short-circuit diffusion effect and the nucleation effect can be enhanced, so that the cement hydration degree is improved; and polyethylene glycol has an internal curing effect, so that the self-constriction of the cement-based material can be reduced.
Owner:ZHENGZHOU UNIV

Culture medium for human metapneumovirus and application

The invention relates to the technical field of biological medicine, and discloses a culture medium for human metapneumovirus and application, the culture medium comprises the following components by mass: 850-920 parts of a basic culture medium; the metabolism reprogramming module is prepared from the following components in parts by weight: 0.05 to 0.15 part of 5-methyltetrahydrofolic acid, 0.3 to 0.7 part of N-acetyl-D-mannosamine and 1.0 to 3.0 parts of sodium dichloroacetate; the immune regulation and control module is prepared from 0.005 to 0.015 part of an RIG-I / MAVS pathway inhibitor; the receptor induction module is prepared from 0.5 to 1.5 parts of all-trans retinoic acid; the redox balance module is prepared from the following components in parts by weight: 0.1 to 0.5 part of pegylated superoxide dismutase and 0.002 to 0.008 part of sodium selenite. According to the method, the proportion of infectious virus particles can be remarkably increased, the generation of defective particles is reduced, meanwhile, the production cycle of host cells is prolonged, large-scale continuous culture is supported, and a high-quality and high-efficiency solution is provided for industrial production of gene therapy vectors and virus vaccines.
Owner:BEIJING HUANUOTAI BIOMEDICAL TECH CO LTD

Pegylated liposomes and methods of use

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
Owner:UNIV OF VIRGINIA PATENT FOUND +1

Treating cancer with long-acting topoisomerase i inhibitor

The disclosure provides method of treating cancer in a patient with ATM-deficient or ATR-deficient tumors, comprising safely and efficaciously administering to the patient PLXO38, a long lasting-PEGylated prodrug of the topoisomerase I inhibitor. The disclosure further provides combination therapies of PLXO38 with inhibitors of the DNA damage response (DDR).
Owner:PROLYNX LLC

Synthetic peptide compounds and methods of use

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.
Owner:REALTA HLDG LLC

PH response bionic nano system for enhancing photodynamic therapy, preparation and application

PendingCN119112838Agood grafting rateHas pH responsive propertiesCell dissociation methodsAntipyreticTherapeutic effectEndogeny
The invention provides a pH response bionic nano system for enhancing photodynamic therapy, preparation and application, and belongs to the field of pharmaceutical preparations, hyaluronic acid is used as an initial carrier to load an endogenous hydrogen sulfide donor SPRC and modify an acid response connexon, and then the hyaluronic acid is crosslinked with a pegylated photosensitizer Ce6 to form acid response nano particles. And finally, coating nano particles with the macrophage membrane through a nano-membrane co-extrusion technology to prepare the pH response type bionic nano system (RAW-HSC) coated with the macrophage membrane. In-vivo and in-vitro experiments show that the pH response type bionic nano system can effectively target an inflammation joint part, a small amount of hydrogen sulfide generated by SPRC release can effectively enhance the photodynamic therapy effect, meanwhile, the pH response type bionic nano system has the advantages of biological safety, pH response release and the like, a new thought is provided for research, development and design of a novel medicament, and the pH response type bionic nano system has wide application prospects. The important significance is realized on the treatment of rheumatoid arthritis.
Owner:MACAU UNIV OF SCI & TECH

Lipid nanoparticle, application thereof and drug delivery carrier

The invention belongs to the field of biological medicine, and particularly relates to lipid nanoparticles, application thereof and a drug delivery carrier. The lipid nanoparticle comprises an ionizable lipid, cholesterol, phospholipid, a pegylated lipid and a sterol substitute, and is characterized in that the ionizable lipid is Lipid 5, the phospholipid is DSPC, the pegylated lipid is 18: 0 mPEG2000 PE, and the sterol substitute is one or more of beta-sitosterol, stigmasterol or stigmasterol or a derivative thereof; the molar ratio of the ionizable lipid to the cholesterol to the phospholipid to the pegylated lipid to the sterol substitute is (40-60): (5-38.5): (5-30): (1-2): (5-38.5). According to the invention, the LNP with unique physicochemical properties is constructed through high synergy of the components, the technical problems of low delivery efficiency and poor specificity of hematopoietic stem progenitor cells in the prior art are solved, and high-efficiency and high-specificity drug delivery of HSPCs in vivo and in vitro is realized. The invention also provides a drug delivery carrier containing the lipid nanoparticles and a preparation method thereof.
Owner:BLOOD TRASFUSION INST CHINESE ACAD OF MEDICAL SCI

Pegylated liposomes and methods of use

Provided herein are PEGylated liposomes, and methods of making and using thereof. The PEGylated liposomes comprise at least a cholesterol, a non-PEGylated neutral lipid, and a PEGylated lipid, wherein the average molecular weight of the PEG component in the PEGylated lipid is about 5000 Daltons or less. The PEGylated liposomes are stable and capable of delivery of an agent for the generation of an immune response, for example an agent for vaccine, therapeutic, or diagnostic uses. Compositions and methods related to making the PEGylated liposomes and using the PEGylated liposomes for stimulating an immune response are also provided.
Owner:UNIV OF VIRGINIA PATENT FOUND +1

Method for detecting Anti-drug antibodies against self-assembling trimeric biologics using an affinity capture elution-protein a / g assay

A method and kit are provided for detecting anti-drug antibodies (ADAs) against self-assembling trimeric biologics, such as XPro1595, a pegylated variant of soluble human Tumor Necrosis Factor, in biological samples, particularly human serum. The method employs an Affinity Capture Elution-Protein A / G (ACE-AG) assay that overcomes non-specific reagent interactions inherent in conventional bridging and standard ACE assays due to the biologic's dynamic monomer exchange. The assay utilizes a two-plate system: a streptavidin-coated plate with biotinylated trimeric biologic captures ADAs, which are eluted, neutralized, and transferred to a protein A / G-coated plate for specific immunoglobulin capture and detection with a sulfo-tagged trimeric biologic via electrochemiluminescence. The kit includes pre-coated plates, labeled biologics, elution and neutralization solutions, assay buffer, confirmatory reagent, and instructions. The assay offers a robust, specific, and sensitive solution for immunogenicity testing of trimeric biologics.
Owner:INMUNE BIO INC

Methods for production of human recombinant arginase 1 and uses thereof

Described are methods for producing recombinant Arginase, such as PEGylated, cobalt-substituted recombinant human Arginase 1. Also described are pharmaceutical compositions comprising such recombinant Arginase, as well as methods of treatment and uses of such recombinant Arginase.
Owner:IMMEDICA PHARMA AB

Metformin-loaded pegylated two-dimensional phosphorene nanosheet as well as preparation method and application thereof

The invention discloses a metformin-loaded pegylated two-dimensional phosphorene nanosheet as well as a preparation method and an application of the metformin-loaded pegylated two-dimensional phosphorene nanosheet. The preparation method comprises the following steps: preparing two-dimensional phosphorene nanosheets from black phosphorus crystals through a liquid phase stripping method; the preparation method comprises the following steps: mixing polyethylene glycol amino with a two-dimensional phosphorene nanosheet to prepare a pegylated two-dimensional phosphorene nanosheet; the preparation method comprises the following steps: mixing metformin with the pegylated two-dimensional phosphorene nanosheet, and removing free metformin, so as to obtain the metformin-loaded pegylated two-dimensional phosphorene nanosheet. The metformin-loaded pegylated phosphorene nanosheet disclosed by the invention has transdermal permeation and anti-oxidative stress capabilities, can deliver a drug into skin tissues, induces angiogenesis of hair follicles and promotes hair regeneration of an androgenetic alopecia animal model by removing excessive ROS (reactive oxygen species) in the surrounding environment of the hair follicles, and is degradable, so that the metformin-loaded pegylated phosphorene nanosheet disclosed by the invention has a good application prospect. The compound is safe and low in toxicity, and has good clinical application prospect and development value.
Owner:GUANGZHOU UNIVERSITY OF CHINESE MEDICINE

Process for providing PEGylated protein composition

Processes for providing a PEGylated protein composition comprising mono-PEGylated protein and oligo-PEGylated protein, and processes for providing mono-PEGylated protein compositions with high yield and productivity are provided. The processes are particularly suitable for providing mono-PEGylated erythropoietin composition. The processes comprise reacting a non-PEGylated protein with a PEGylation reagent to produce a mixture comprising non-PEGylated, mono-PEGylated and oligo-PEGylated protein, subjecting the mixture to a step of anion exchange chromatography, and recycling non-PEGylated protein into further PEGylation reactions.
Owner:F HOFFMANN LA ROCHE INC

Preparation method of pegylated black phosphorus loaded bio-enzyme nano-particles with acoustic catalysis performance

The invention discloses a preparation method of a pegylation acoustic catalysis effect black phosphorus loaded biological enzyme nano particle, which is a novel nano composite material based on material chemistry and pharmaceutical chemistry, and bacterial keratitis is treated by using the unique acoustic catalysis property of the nano particle. Nanoparticle synthesis mainly comprises the following steps: 1) pretreatment of commercial black phosphorus; (2) uploading biological enzyme iron-curcumin to black phosphorus in situ; and (3) synthesizing hyaluronic acid coupled phospholipid polyethylene glycol (DSPE-coated PEG2000-HA) and modifying the biological enzyme black phosphorus nanoparticles. The finally obtained nano composite material has good biocompatibility, ocular surface adhesion, biological enzyme activity and acoustic catalytic treatment effect on bacterial biofilm infection of eyes.
Owner:EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Lipid-pegylated compounds, preparations and uses thereof

Embodiments of the present disclosure relate to lipid-PEGylated solid support and phosphoramidites derivatives, methods for preparing the same, and their uses in the delivery of oligonucleotide drugs to the cellular targets.
Owner:HONGENE BIOTECH CORPORATION

Lipid nano-particles for fish in-vivo skin gene editing and application of lipid nano-particles

The invention relates to lipid nanoparticles for fish in-vivo skin gene editing and application of the lipid nanoparticles, and belongs to the technical field of fish gene editing. The lipid nanoparticle for fish in-vivo skin gene editing comprises a gene editing element and a lipid layer, wherein the lipid layer wraps the surface of the gene editing element; the gene editing element is a CRISPR (clustered regularly interspaced short palindromic repeats) / Cas9 (CRISPR associated protein 9) ribonucleoprotein compound or nucleic acid for coding the compound; the lipid nanoparticle carrier comprises ionizable cationic lipid, auxiliary lipid, cholesterol, pegylated lipid and permanent cationic lipid, and the lipid nanoparticle carrier comprises the following components in parts by mole: 15 parts of ionizable cationic lipid, 25-30 parts of auxiliary lipid, 30 parts of cholesterol, 3 parts of pegylated lipid and 7 parts of permanent cationic lipid. The formula is high in pertinence, high in editing efficiency, simple, convenient and safe to operate and wide in application prospect.
Owner:SANYA INST OF OCEANOGRAPHY OCEAN UNIV OF CHINA

An improved method for separating and detecting of free or residual polyethylene glycol in pegylated protein mixture

The present invention relates to an improved method for separating and detecting of free or residual polyethylene glycol (PEG) in pegylated protein mixture. In particular, the method improves sensitivity, effective separation, and robustness of the quantification of free or residual PEG and related substance present in pegylated protein mixture which obtained as drug substance or drug product.
Owner:KASHIV BIOSCIENCES LLC

PHARMACOLOGICAL PRODUCT FOR ENZYME THERAPY FOR THE TREATMENT OF HOMOCYSTRINURIA

This description provides formulations for a pharmaceutical product comprising a PEGylated CBS protein having the amino acid sequence SEQ ID NO: 1. Dosages and dosage regimens are provided for the treatment of homocystinuria in a subject in need. In addition, dosages and dosage regimens are also provided for reducing homocysteine ​​(Hcy) levels or increasing cysteine ​​(Cys) and / or cystathionine (Cth) levels in a subject in need.
Owner:TRAVERE THERAPEUTICS SWITZERLAND GMBH +3

Compositions and methods for organ and cell targeted delivery

The present disclosure provides compositions which facilitate preferential targeting or delivery of a therapeutic agent to a particular organ, cell, or tissue. The presently disclosed compositions comprise lipid nanoparticles formed from a covalent-bond forming lipid, a cationic lipid, and, in some embodiments, a steroid or sterol, a phospholipid, and a PEG lipid.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Application of pegylated irinotecan in treatment of triple negative breast cancer disease

The invention discloses an application of pegylated irinotecan in preparation of a medicine for preventing and / or treating triple-negative breast cancer brain metastasis diseases, which is shown by in-vivo imaging observation and lifetime observation of high, medium and low dose groups of pegylated irinotecan with a specific structure. The high-dose group, the medium-dose group and the low-dose group all have a definite anti-tumor effect, bioluminescence signal values are inhibited to different degrees, the lifetime is prolonged, and the lifetime of the high-dose group and the lifetime of the medium-dose group are remarkably longer than that of the NKTR-102 group.
Owner:JENKEM TECH CO LTD TIANJIN

Gas-filled microvesicles with ligand

Formulations of gas-filled microvesicles comprising a ligand, which may advantageously be used in methods for separating cells or biological materials. The formulations comprise a phospholipid and a suitable mixture of a pegylated phospholipid and of a pegylated phospholipid comprising a ligand.
Owner:BRACCO SUISSE SA